Search
01/11/2025
Phase II of sunitinib plus nivolumab in advanced alveolar soft-part sarcoma results from the GEIS, ISG and UCL IMMUNOSARC II study
Muñiz, NH, Strauss, S, Redondo, A, Palmerini, E, Gaffaro, GJM, Chamberlain, FE, Martinez, V, Ibrahim, T, Trufero, JM, Morales, CMV, Billalabeitia, EG, Lleida, RT, Jiménez, CL, Mukherjee, U, Wan, S, Ramos, R, Garcia, AMG, Moura, DD, Martin-Broto, J. Phase II of sunitinib plus nivolumab in advanced alveolar soft-part sarcoma results from the GEIS, ISG and UCL IMMUNOSARC II study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3296. PMID:. IF:65.400(Q1/1D).
01/11/2025
Evaluation of a non-pharmacological skin care intervention for the prevention and treatment of skin toxicities induced by immunotherapy in oncology patients
Lopez, JS, Besora, CP, Malaret, M, Joaquín, AB, Recio, SM, Momblan, AM, Dalmau, GM, Majem, M. Evaluation of a non-pharmacological skin care intervention for the prevention and treatment of skin toxicities induced by immunotherapy in oncology patients. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3451. PMID:. IF:65.400(Q1/1D).
01/11/2025
Navigating regulatory complexity in combined studies under clinical trial and in vitro diagnostic regulations: Lessons from the CHONQUER study on molecular prescreening for IDH1 mutation in chondrosarcoma
Blay, JY, Lleida, RT, Martin-Broto, J, Caetano, C, De Haan, JJ, Debruyne, C, Desar, I, Duffaud, F, Gelderblom, H, Gennigens, C, Italiano, A, Colomo, LJ, Lapeire, L, Mazzeo, F, Philip, J, Striefler, JK, Svobodova, M, Tala, I, Morales, CMV, Stacchiotti, S. Navigating regulatory complexity in combined studies under clinical trial and in vitro diagnostic regulations: Lessons from the CHONQUER study on molecular prescreening for IDH1 mutation in chondrosarcoma. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3359. PMID:. IF:65.400(Q1/1D).
01/11/2025
Personalizing antiemetic prophylaxis for patients at high emetic risk: Results from the MyRisk Trial
Molasiotis, A, Jordan, K, Karthaus, M, Dranitsaris, G, Roeland, EJ, Schwartzberg, LS, Bonizzoni, E, Vazquez, EB, Buchler, T, Cheng, Y, Christoph, DCC, Alfonso, PG, Lu, X, Majem, M, Mavroudis, D, Syrigos, K, Tomlins, E, Zhou, Z, Zimovjanova, M, Aapro, MS. Personalizing antiemetic prophylaxis for patients at high emetic risk: Results from the MyRisk Trial. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3413. PMID:. IF:65.400(Q1/1D).
01/11/2025
Circulating tumor DNA (ctDNA) for minimal disease detection in oropharyngeal cancer (OPC): results from the CAPTION Spanish prospective study
Sepulveda, ZV, Tous, S, Quiros, B, Pena, GP, Castro, JB, Serrahima, MP, Galiana, IL, Marí, A, Brunet, A, Bermejo, JO, Cirauqui, BC, Diez, AF, Leon, X, Sumarroca, A, Giner, M, Clavero, O, Goma, M, Pavon, MA, Alemany, L, Bernal, MO. Circulating tumor DNA (ctDNA) for minimal disease detection in oropharyngeal cancer (OPC): results from the CAPTION Spanish prospective study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2028. PMID:. IF:65.400(Q1/1D).
01/11/2025
Pharmacogenetics in advanced Parkinson's disease
Kulisevsky, J, García-Ruíz, P, Outeiro, TF, Gurevich, T, Klivènyi, P, Van Laar, T, Milanov, I, Pirker, W, Popescu, BO, Toft, M, Szász, JA. Pharmacogenetics in advanced Parkinson's disease. JOURNAL OF NEURAL TRANSMISSION. 2025; 132(11)DOI:10.1007/s00702-025-03057-0. PMID:41222708. IF:4.000(Q1/2D).